HC Wainwright Has Negative Outlook for Genelux Q1 Earnings

Genelux Co. (NASDAQ:GNLX) – Research analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Genelux in a report released on Monday, March 31st. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.25) for the quarter, down from their previous forecast of ($0.16). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.03) EPS, FY2026 earnings at ($1.03) EPS, FY2027 earnings at ($0.76) EPS, FY2028 earnings at $0.32 EPS and FY2029 earnings at $1.32 EPS.

Genelux Price Performance

NASDAQ GNLX opened at $2.50 on Thursday. Genelux has a 12 month low of $1.60 and a 12 month high of $5.89. The company has a market capitalization of $86.82 million, a price-to-earnings ratio of -2.63 and a beta of -1.41. The firm’s fifty day moving average price is $4.03 and its 200 day moving average price is $3.10.

Genelux (NASDAQ:GNLX) last posted its earnings results on Friday, March 28th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09).

Institutional Trading of Genelux

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Marshall Wace LLP raised its position in Genelux by 51.4% in the 4th quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock valued at $368,000 after purchasing an additional 52,958 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Genelux in the 4th quarter valued at $41,000. LPL Financial LLC raised its position in Genelux by 72.3% during the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock worth $222,000 after buying an additional 39,516 shares during the last quarter. Virtu Financial LLC acquired a new position in Genelux during the 4th quarter worth approximately $25,000. Finally, LifeSteps Financial Inc. raised its stake in shares of Genelux by 11.1% during the 4th quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock worth $205,000 after buying an additional 8,715 shares in the last quarter. Institutional investors and hedge funds own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.